IMC Chicago’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $818M | Sell |
889,800
-260,400
| -23% | -$264M | 0.29% | 50 |
|
|
2025
Q4 | $1.24B | Sell |
1,150,200
-55,100
| -5% | -$52.7M | 0.45% | 41 |
|
|
2025
Q3 | $920M | Buy |
1,205,300
+372,500
| +45% | +$277M | 0.33% | 48 |
|
|
2025
Q2 | $649M | Buy |
832,800
+206,800
| +33% | +$161M | 0.29% | 47 |
|
|
2025
Q1 | $517M | Sell |
626,000
-257,100
| -29% | -$214M | 0.29% | 43 |
|
|
2024
Q4 | $682M | Buy |
883,100
+173,500
| +24% | +$144M | 0.32% | 37 |
|
|
2024
Q3 | $629M | Buy |
709,600
+108,300
| +18% | +$97.4M | 0.34% | 37 |
|
|
2024
Q2 | $544M | Buy |
601,300
+18,400
| +3% | +$14.7M | 0.33% | 36 |
|
|
2024
Q1 | $453M | Buy |
582,900
+34,700
| +6% | +$24.7M | 0.28% | 42 |
|
|
2023
Q4 | $320M | Buy |
548,200
+147,400
| +37% | +$86M | 0.21% | 49 |
|
|
2023
Q3 | $215M | Buy |
400,800
+147,600
| +58% | +$76.1M | 0.19% | 46 |
|
|
2023
Q2 | $119M | Buy |
253,200
+107,800
| +74% | +$45.2M | 0.11% | 84 |
|
|
2023
Q1 | $49.9M | Buy |
145,400
+13,800
| +10% | +$4.65M | 0.06% | 170 |
|
|
2022
Q4 | $48.1M | Sell |
131,600
-34,100
| -21% | -$12.1M | 0.08% | 159 |
|
|
2022
Q3 | $53.6M | Buy |
165,700
+75,500
| +84% | +$23.9M | 0.07% | 129 |
|
|
2022
Q2 | $29.2M | Buy |
90,200
+46,000
| +104% | +$13.8M | 0.04% | 214 |
|
|
2022
Q1 | $12.7M | Sell |
44,200
-6,700
| -13% | -$1.72M | 0.01% | 421 |
|
|
2021
Q4 | $14.1M | Sell |
50,900
-12,200
| -19% | -$3.09M | 0.01% | 429 |
|
|
2021
Q3 | $14.6M | Sell |
63,100
-32,000
| -34% | -$7.9M | 0.02% | 425 |
|
|
2021
Q2 | $21.8M | Sell |
95,100
-4,900
| -5% | -$984K | 0.03% | 310 |
|
|
2021
Q1 | $18.7M | Buy |
100,000
+25,900
| +35% | +$5.07M | 0.03% | 310 |
|
|
2020
Q4 | $12.5M | Buy |
74,100
+51,500
| +228% | +$7.69M | 0.02% | 359 |
|
|
2020
Q3 | $3.35M | Sell |
22,600
-24,100
| -52% | -$3.73M | 0.01% | 482 |
|
|
2020
Q2 | $7.67M | Sell |
46,700
-8,000
| -15% | -$1.23M | 0.02% | 302 |
|
|
2020
Q1 | $7.59M | Sell |
54,700
-1,300
| -2% | -$179K | 0.02% | 244 |
|
|
2019
Q4 | $7.36M | Buy |
56,000
+19,700
| +54% | +$2.28M | 0.02% | 277 |
|
|
2019
Q3 | $4.06M | Buy |
36,300
+1,400
| +4% | +$156K | 0.01% | 326 |
|
|
2019
Q2 | $3.87M | Sell |
34,900
-17,400
| -33% | -$2.05M | 0.01% | 324 |
|
|
2019
Q1 | $6.79M | Buy |
52,300
+45,100
| +626% | +$5.48M | 0.02% | 197 |
|
|
2018
Q4 | $833K | Buy |
+7,200
| New | +$804K | ﹤0.01% | 484 |
|
Other funds holding LLY
VCM
VPM
IMC Chicago's LLY Position: Q3 2025 in Review
IMC Chicago sold out of Eli Lilly (LLY) in Q3 2025, closing a stake of 17,293 shares — an estimated $12.9M sold.
IMC Chicago first reported a position in LLY in Q4 2018 and held it in 4 quarters. The position peaked at $37.6M in Q4 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- IMC Chicago reported no remaining Eli Lilly position as of Q3 2025 after selling out during the quarter.
- IMC Chicago sold 17,293 Eli Lilly shares in Q3 2025, an estimated $12.9M.
- IMC Chicago first reported a position in Eli Lilly in Q4 2018 and held it in 4 quarters.
- IMC Chicago's Eli Lilly position peaked at $37.6M in Q4 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.